Progressive Supranuclear Palsy

7
Pipeline Programs
5
Companies
7
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
5
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 6 programs with unclassified modality

On Market (1)

Approved therapies currently available

U
RASAGILINE MESYLATEApproved
rasagiline
Unknown Company
oral2024

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Teva
TevaIsrael - Petach Tikva
1 program
1
RasagilinePhase 31 trial
Active Trials
NCT01187888Terminated44Est. Jun 2012
UP
UCB PharmaBelgium - Brussels
3 programs
2
UCB0107Phase 11 trial
bepranemabPhase 1Monoclonal Antibody1 trial
Verily Study WatchN/A1 trial
Active Trials
NCT05501431Completed100Est. Sep 2024
NCT04658199Active Not Recruiting19Est. Dec 2027
NCT04185415Completed25Est. Nov 2021
Biogen
BiogenCAMBRIDGE, MA
1 program
1
BIIB092Phase 11 trial
Active Trials
NCT02460094Completed48Est. Oct 2016
C2N Diagnostics
C2N DiagnosticsMO - St. Louis
1 program
1
Single dose C2N-8E12Phase 11 trial
Active Trials
NCT02494024Completed32Est. Aug 2016
Life Molecular Imaging
Life Molecular ImagingGermany - Berlin
1 program
1
[18F]-PI2620Phase 11 trial
Active Trials
NCT05187546CompletedEst. Mar 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
TevaRasagiline
Life Molecular Imaging[18F]-PI2620
UCB PharmaUCB0107
UCB Pharmabepranemab
BiogenBIIB092
C2N DiagnosticsSingle dose C2N-8E12
UCB PharmaVerily Study Watch

Clinical Trials (7)

Total enrollment: 268 patients across 7 trials

NCT01187888TevaRasagiline

Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy

Start: Jan 2010Est. completion: Jun 201244 patients
Phase 3Terminated
NCT05187546Life Molecular Imaging[18F]-PI2620

Test-retest Study With [18F]PI-2620 in PSP-RS and NDC

Start: Mar 2022Est. completion: Mar 2024
Phase 1Completed
NCT04658199UCB PharmaUCB0107

A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy

Start: Nov 2020Est. completion: Dec 202719 patients
Phase 1Active Not Recruiting
NCT04185415UCB Pharmabepranemab

A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)

Start: Dec 2019Est. completion: Nov 202125 patients
Phase 1Completed
NCT02460094BiogenBIIB092

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy

Start: Oct 2015Est. completion: Oct 201648 patients
Phase 1Completed
NCT02494024C2N DiagnosticsSingle dose C2N-8E12

Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy

Start: Jul 2015Est. completion: Aug 201632 patients
Phase 1Completed
NCT05501431UCB PharmaVerily Study Watch

Personalized Parkinson Project PSP Cohort

Start: May 2021Est. completion: Sep 2024100 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space